Overall responses and survival in RCC on pegilodecakin with anti-PD-1

被引：0

作者：

Naing, A. ^{[1
]}

Infante, J. R. ^{[2
]}

Wong, D. J. ^{[3
]}

Korn, W. M. ^{[4
]}

Aljumaily, R. ^{[5
]}

Papadopoulos, K. P. ^{[6
]}

Autio, K. A. ^{[7
]}

Pant, S. ^{[1
]}

Bauer, T. M. ^{[2
]}

Drakaki, A. ^{[3
]}

Daver, N. G. ^{[1
]}

Hung, A. ^{[8
]}

Verma, R. ^{[8
]}

Ratti, N. ^{[8
]}

McCauley, S. ^{[8
]}

Van Vlasselaer, P. ^{[8
]}

Tannir, M. ^{[1
]}

Oft, M. ^{[8
]}

机构：

[1] MDACC, Houston, TX USA

[2] SCRI, Nashville, TN USA

[3] Univ Calif Los Angeles, Los Angeles, CA USA

[4] Univ Calif San Francisco, San Francisco, CA 94143 USA

[5] OUHSC, Oklahoma City, OK USA

[6] START, San Antonio, TX USA

[7] MSKCC, New York, CA USA

[8] ARMO LILLY Redwood City, Redwood City, CA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2019年 / 110卷

关键词：

D O I：

10.1016/j.ejca.2019.01.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S1 / S2

页数：2

共 50 条

[31] Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
Frantz Dupuis
Laurence Lamant
Emilie Gerard
Nouritza Torossian
Leonor Chaltiel
Thomas Filleron
Marie Beylot-Barry
Caroline Dutriaux
Sorilla Prey
Audrey Gros
Marie-Laure Jullie
Nicolas Meyer
Béatrice Vergier
[J]. British Journal of Cancer, 2018, 119 : 193 - 199
[32] Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma
Feng, Liang
Yin, Ke
Zhang, Suxin
Chen, Zhong
Bao, Yang
Li, Tianke
[J]. CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2723 - 2731
[33] The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4
Parvini, Sasan
Majidpoor, Jamal
Mortezaee, Keywan
[J]. PATHOLOGY RESEARCH AND PRACTICE, 2023, 247
[34] Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma
de Velasco, Guillermo
Krajewski, Katherine M.
Albiges, Laurence
Awad, Mark M.
Bellmunt, Joaquim
Hodi, F. Stephen
Choueiri, Toni K.
[J]. CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01) : 12 - 17
[35] Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
Dupuis, Frantz
Lamant, Laurence
Gerard, Emilie
Torossian, Nouritza
Chaltiel, Leonor
Filleron, Thomas
Beylot-Barry, Marie
Dutriaux, Caroline
Prey, Sorilla
Gros, Audrey
Jullie, Marie-Laure
Meyer, Nicolas
Vergier, Beatrice
[J]. BRITISH JOURNAL OF CANCER, 2018, 119 (02) : 193 - 199
[36] T cell Bim levels reflect responses to anti-PD-1 cancer therapy
Dronca, Roxana S.
Liu, Xin
Harrington, Susan M.
Chen, Lingling
Cao, Siyu
Kottschade, Lisa A.
McWilliams, Robert R.
Block, Matthew S.
Nevala, Wendy K.
Thompson, Michael A.
Mansfield, Aaron S.
Park, Sean S.
Markovic, Svetomir N.
Dong, Haidong
[J]. JCI INSIGHT, 2016, 1 (06)
[37] Anti-PD-1: When to Stop Treatment
Jansen, Y.
van der Veldt, A. A. M.
Awada, G.
Neyns, B.
[J]. CURRENT ONCOLOGY REPORTS, 2022, 24 (07) : 905 - 915
[38] A potential biomarker for anti-PD-1 immunotherapy
Goswami, Sangeeta
Basu, Sreyashi
Sharma, Padmanee
[J]. NATURE MEDICINE, 2018, 24 (02) : 123 - 124
[39] Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy
Hamada, Kazuyuki
Yoshimura, Kiyoshi
Hirasawa, Yuya
Hosonuma, Masahiro
Murayama, Masakazu
Narikawa, Yoichiro
Ariizumi, Hirotsugu
Ohkuma, Ryotaro
Shida, Midori
Kubota, Yutaro
Matsukuma, Satoshi
Ishiguro, Tomoyuki
Sambe, Takehiko
Horiike, Atsushi
Kuramasu, Atsuo
Wada, Satoshi
Tsurutani, Junji
Inoue, Eisuke
Uchida, Naoki
Kiuchi, Yuji
Kobayashi, Shinichi
Hoffman, Robert M.
Tsunoda, Takuya
[J]. ANTICANCER RESEARCH, 2021, 41 (10) : 4985 - 4993
[40] Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era
Lamba, Nayan
Ott, Patrick A.
Iorgulescu, J. Bryan
[J]. JAMA NETWORK OPEN, 2022, 5 (08) : E2225459

← 1 2 3 4 5 →